Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 3/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9437194 | 0.84 | PTGS2 (0.47) | PDGFRBPDGFRAQDPRACMSDTRIM24 | |
| SCHEMBL27553177 | 0.78 | QDPR (0.70) | QDPRCD274 | |
| SCHEMBL17335722 | 0.78 | KDM1A (0.46) | PDGFRBPDGFRAKDM1APAX8CD274 | |
| SCHEMBL18487978 | 0.75 | ACMSD (0.41) | PDGFRBPDGFRAACMSDPAX8HDAC1 | |
| SCHEMBL29968074 | 0.75 | PDGFRB (0.43) | PDGFRBPDGFRAQDPRACMSDTRIM24 | |
| SCHEMBL1257285 | 0.75 | ACMSD (0.49) | ACMSDHDAC1HDAC2PTGS2 | |
| SCHEMBL8939884 | 0.74 | KCNH2 (0.47) | PDGFRBPDGFRAACMSDALDH1A1PTGS2 | |
| SCHEMBL30868397 | 0.74 | ALDH1A1 (0.51) | PDGFRBPDGFRAACMSDALDH1A1 | |
| SCHEMBL1630255 | 0.73 | NPC1 (0.57) | PDGFRBPDGFRAACMSDPTGS2 | |
| SCHEMBL6641330 | 0.73 | PDE4A (0.50) | PDGFRBPDGFRAQDPRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790870-A1 | CYCLOPENTANE COMPOUNDS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215268-A1 | CYCLOPENTANE COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | PDGFRB 974/4885PDGFRA 2103/4885QDPR 1884/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | PDGFRB 974/4885PDGFRA 2103/4885QDPR 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.